Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Usage of antiplatelet agents and cardiac procedures such as coronary angioplasty has
dramatically improved the morbidity and mortality associated with coronary artery disease. In
patients with a coronary stent, dual antiplatelet therapy is recommended. Aspirin is the main
antiplatelet agent used. For many years, clopidogrel was the second antiplatelet of choice.
Recent studies have revealed new antiplatelet drugs that can substitute clopidogrel, one of
which is ticagrelor. The degree to which ticagrelor reduced the overall mortality compared to
clopidogrel in the PLATO trial suggested that ticagrelor possibly has a pleiotropic effect
and that the reduction in mortality is not simply due to its antiplatelet effects. The
ticagrelor molecule resembles adenosine. Adenosine has been shown to be cardioprotective.
The aim of this project is to study the effects of ticagrelor on the arterial system using a
noninvasive method. The study will employ the measurement of peripheral endothelial function
of patients who undergo percutaneous coronary intervention who are on ticagrelor vs.
clopidogrel using a cross over trial design.